<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180121038462N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-03-11</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of two methods of Bupivacaine and Fentanyl injection in lower limb fracture surgeries</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of fractionated dose of Bupivacaine and Fentanyl versus bolus dose injection in spinal anesthesia in lower limb fracture surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-04-08</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/29087</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are assigned to two groups of intervention and control by choosing one of the envelopes, Blinding description: In this study, the patients and person who performs spinal injections are not blind to the blind study, and only researcher is blind to the study. In this way, the researcher is not present in the room at the time of injection of anesthetic drug.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Lower limb fracture surgery. Condition 2: Lower limb fracture surgery. Condition 3: Lower limb fracture surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in intervention group, will receive half dose of  15 milligram of Bupivacaine 0.5 % and 25 micro gram of Fentanyl at first, and after 45 seconds half the other drug will be injected. Intervention 2: Control group: Patients in control group, will receive bolus dose of 15 milligram of Bupivacaine 0.5 % and 25 micro gram of Fentanyl and then will be placed in supine position after 45 seconds.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I have not yet decided on this.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Qazale Khaef</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Medicine, Iran University of Medical Sciences, Hemat Highway next to Milad Tower</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 86701</telephone>
        <email>khaef.gh@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Poya Derakhshan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Medicine, Iran University of Medical Sciences, Hemat Highway next to Milad Tower</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>144961459535</zip>
        <telephone>+98 21 6535 2326</telephone>
        <email>pooyaderakh@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients undergoing surgery for lower limb fractures
Age 18 to 50 years old
ASA 1 to 2</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with absolute spinal anesthesia contraindication
Refusal of the patient
Localized sepsis
Allergy to the anesthetic drugs
Patient's inability to maintain position during the procedure
Increase ICP
Spinal relative contraindications such as myelopathy or peripheral neuropathy
Spinal stenosis
history of spinal surgery
Multiple sclerosis
Spina bifida
Aortic thrombosis
Hypovolemia
Hereditary coagulopathies
Thromboprofylaxis (ambulatory lung)
Systemic infections
Patients with a BMI greater than 35
Spinal deformities
Patients who did not succeed in spinal anesthesia
Patients whose length of operation is longer than their spinal anesthesia length</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>s70-s79</hc_code>
      <hc_code>S80-S89</hc_code>
      <hc_code>S90-S99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Injuries to the hip and thigh</hc_keyword>
      <hc_keyword>Injuries to the knee and lower leg</hc_keyword>
      <hc_keyword>Injuries to the ankle and foot</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in intervention group, will receive half dose of  15 milligram of Bupivacaine 0.5 % and 25 micro gram of Fentanyl at first, and after 45 seconds half the other drug will be injected.</i_keyword>
      <i_keyword>Control group: Patients in control group, will receive bolus dose of 15 milligram of Bupivacaine 0.5 % and 25 micro gram of Fentanyl and then will be placed in supine position after 45 seconds.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood pressure. Timepoint: 24 hours after surgery. Method of measurement: Noninvasive Blood Pressure Amplifier (NIBP).</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: 24 hours after surgery. Method of measurement: Electrocardiography.</prim_outcome>
      <prim_outcome>Pruritus. Timepoint: 24 hours after surgery. Method of measurement: Observation.</prim_outcome>
      <prim_outcome>Urinary retention. Timepoint: 24 hours after surgery. Method of measurement: Observation.</prim_outcome>
      <prim_outcome>Shivering. Timepoint: 24 hours after surgery. Method of measurement: Observatioon.</prim_outcome>
      <prim_outcome>Respiratory distress. Timepoint: 24 hours after surgery. Method of measurement: Clinical feature.</prim_outcome>
      <prim_outcome>Nausea. Timepoint: 24 hours after surgery. Method of measurement: Observation.</prim_outcome>
      <prim_outcome>Vomiting. Timepoint: 24 hours after surgery. Method of measurement: Observation.</prim_outcome>
      <prim_outcome>Onset of sensory block. Timepoint: After the injection of anesthetic drug. Method of measurement: Pinprick test.</prim_outcome>
      <prim_outcome>Onset of motor block. Timepoint: After the injection of anesthetic drug. Method of measurement: Modified bromage scale.</prim_outcome>
      <prim_outcome>Highest level of sensory block. Timepoint: After the injection of anesthetic drug. Method of measurement: Pinprick test.</prim_outcome>
      <prim_outcome>Duration of sensory block. Timepoint: After the injection of anesthetic drug. Method of measurement: Modified bromage scale.</prim_outcome>
      <prim_outcome>Duration of motor block. Timepoint: After the injection of anesthetic drug. Method of measurement: Pinprick test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-02-19</approval_date>
        <contact_name>Ethics committee of Shahid Iran University of Medical Science</contact_name>
        <contact_address>Hemat Highway next to Milad Tower, Iran University of Medical Sciences, Faculty of Medicine Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
